FDA Brief

Warning letters Drugs

FDA warning letter to

Glicerinas Industriales, S.A. de C.V.

High riskIssued Jan 16, 2024Posted Jan 23, 2024Center for Drug Evaluation and Research | CDER

FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.

What happened

FDA inspected the Zapopan facility from May 8 to 12, 2023. It found the company failed to test incoming high-risk drugs such as glycerin for DEG/EG and failed to investigate particulate contamination (colored particles, insects, hair, fibers) in repackaged glycerin and propylene glycol; the company released contaminated lots without adequate investigation. FDA also placed the firm on Import Alert 66-40.

What FDA found

  1. Failed to test the identity of each batch of incoming production material and to qualify suppliers before relying on their certificates of analysis.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. Failed to adequately test high-risk glycerin for diethylene glycol (DEG) and ethylene glycol (EG) contamination.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. Failed to investigate deviations from quality specifications, including particulate contamination in repackaged drugs.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. Did not reject lots contaminated with colored particulates, insects, hair, and fibers, and released them to customers without a full root-cause investigation.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  5. Failed to assess the safety risk of contaminated drugs released to customers, including customer notification.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  6. Failed to implement corrective and preventive action until after FDA cited the firm.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions, and to provide DEG/EG test results from retained high-risk lots within 30 calendar days, plus independent reviews and action plans. FDA also recommends a qualified CGMP consultant perform a six-system audit.

Who should pay attention

  • drug manufacturers that buy API or excipients from this repackager
  • brands using glycerin or propylene glycol in finished pharmaceuticals
  • quality teams managing supplier qualification and incoming material testing

This is a summary. Read the original letter on fda.gov.

Glicerinas Industriales, S.A. de C.V.'s FDA history

  1. Glicerinas Industriales, S.A. de C.V.

    Glicerinas Industriales refused a pre-announced FDA inspection; FDA calls its glycerin drugs adulterated and placed firm on Import Alert 66-79.

    High risk

Full company page

Similar letters to other companies

  1. Q’s American Best Trading Inc.

    FDA warned Q’s American Best Trading that it lacked required foreign supplier verification for imported cinnamon, corn, and instant noodles.

    High risk
  2. Carive Imports Inc.

    Carive Imports failed to provide required records for imported garlic paste, cookies, noodles and pigeon peas after FDA requested them.

    High risk
  3. Mseafood Corporation

    Mseafood Corporation lacked required foreign supplier verification for imported cocktail sauce, FDA says.

    Medium
  4. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk